ACN Newswire
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsinLead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of actionVILNIUS, Lithuania, July 15, 2025 – (ACN Newswire) – AATec Medical GmbH (“AATec”), a biotech company developing a multi-product platform for the treatment of respiratory diseases…
Read More
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsinLead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of actionVILNIUS, Lithuania, July 15, 2025 – (ACN Newswire) – AATec Medical GmbH (“AATec”), a biotech company developing a multi-product platform for the treatment of respiratory diseases…